Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The researchers sought to assess safety and tolerability of inhaled GH in children and to estimate relative bioavailability and biopotency between inhaled GH and sc GH.

Why It Was Studied

Delivery of GH via inhalation is a potential alternative to injection.

Who Took Part

By PubMed's age tags, the people studied were children and teenagers, both men and women.

This pediatric multicenter, randomized, double-blind, placebo-controlled, crossover trial had two 7-d treatment phases.

Patients received inhaled GH and sc GH in the alternate phase.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, crossover and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

Placebo was administered by the route opposite from active drug.

GH and IGF-I levels were measured at multiple time points.

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Administration, Inhalation, Growth Disorders, Human Growth Hormone and Patient Satisfaction.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.